Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.40 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18489859 | 1.00 | KDM4E (0.44) | KDM4ENPY5RSIGMAR1LTB4RLTB4R2 | |
| SCHEMBL16202140 | 0.88 | KDM4E (0.58) | KDM4ESIGMAR1LTB4RLTB4R2CTSB | |
| SCHEMBL18522832 | 0.88 | KDM4E (0.58) | KDM4ESIGMAR1LTB4RLTB4R2CTSB | |
| SCHEMBL18511509 | 0.87 | KDM4E (0.47) | KDM4ESIGMAR1LTB4RLTB4R2CTSL | |
| SCHEMBL18511507 | 0.87 | KDM4E (0.47) | KDM4ESIGMAR1LTB4RLTB4R2MEN1 | |
| SCHEMBL18511513 | 0.86 | KDM4E (0.46) | KDM4ESIGMAR1LTB4RLTB4R2LMNA | |
| SCHEMBL18522846 | 0.86 | KDM4E (0.46) | KDM4ESIGMAR1LTB4RLTB4R2LMNA | |
| Hydrochloric Acid SCHEMBL17203024 | 0.85 | KDM4E (0.45) | KDM4ESIGMAR1LTB4RLTB4R2LMNA | |
| Hydrochloric Acid SCHEMBL18489871 | 0.85 | KDM4E (0.45) | KDM4ESIGMAR1LTB4RLTB4R2LMNA | |
| SCHEMBL19393993 | 0.84 | MAPT (0.44) | KDM4ENPY5RPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-12-06 | — | — | US | disclosed |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2022-01-11 | — | — | US | disclosed |
| CN-108650882-B | Compositions for treating cancers expressing IGF-1R | 皮埃尔法布雷医药公司 | 2021-09-17 | — | — | CN | disclosed |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2021-02-11 | — | — | US | disclosed |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2021-02-09 | — | — | US | disclosed |
| US-10858423-B2 | Composition for the treatment of IGF-1R expressing cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-12-08 | — | — | US | disclosed |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2020-08-27 | — | — | US | disclosed |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2020-04-28 | — | — | US | disclosed |
| CN-106470708-B | Antibody-drug-conjugates and their use for the treatment of cancer | 皮埃尔法布雷医药公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190269788-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2019-09-05 | — | — | US | disclosed |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2019-06-11 | — | — | US | disclosed |
| CN-108650882-A | Composition for the cancer for treating expression IGF-1R | 皮埃尔法布雷医药公司 | 2018-10-12 | — | — | CN | disclosed |
| EP-3368093-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | Pierre Fabre Medicament (FR) | 2018-09-05 | — | — | EP | disclosed |
| CN-106456800-B | IGF-1R antibody-drug-conjugates and uses thereof for the treatment of cancer | 皮埃尔法布雷医药公司 | 2018-05-01 | — | — | CN | disclosed |
| US-9669106-B2 | Conjugate of monomethyl auristatin F and trastuzumab and its use for the treatment of cancer | PIERRE FABRE MEDICAMENT (FR) | 2017-06-06 | — | — | US | disclosed |
| WO-2017072196-A1 | COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-05-04 | — | — | WO | disclosed |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-04-27 | — | — | US | disclosed |
| CN-106470708-A | Antibody-drug-conjugates and their use for the treatment of cancer | 皮埃尔法布雷医药公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106456800-A | IGF-1R antibody-drug-conjugates and uses thereof for the treatment of cancer | 皮埃尔法布雷医药公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858423-B2 | Composition for the treatment of IGF-1R expressing cancer | IGF1R, IGFBP1, IGFBP5 | KDM4E 1718/4885NPY5R 129/4885SIGMAR1 3177/4885 |
| US-20170043032-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | KDM4E 1659/4885NPY5R 3229/4885SIGMAR1 4684/4885 |
| US-20200270352-A1 | IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | IGF1R, IGFBP1, IGFBP5 | KDM4E 1679/4885NPY5R 661/4885SIGMAR1 2924/4885 |
| US-20170112943-A1 | CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER | AURKC, AURKA, EGFR | KDM4E 678/4885NPY5R 3433/4885SIGMAR1 4578/4885 |
| US-10912841-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | KDM4E 2202/4885NPY5R 3672/4885SIGMAR1 4045/4885 |
| US-10633448-B2 | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | IGF1R, IGFBP1, IGFBP5 | KDM4E 1679/4885NPY5R 661/4885SIGMAR1 2924/4885 |
| US-11517625-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DDOST, DAD1, KRTCAP2 | KDM4E 2202/4885NPY5R 3672/4885SIGMAR1 4045/4885 |
| US-11219693-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | DAD1, DDOST, KRTCAP2 | KDM4E 2260/4885NPY5R 3548/4885SIGMAR1 4112/4885 |
| US-20190269788-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | KRTCAP2, DDOST, DAD1 | KDM4E 1659/4885NPY5R 3229/4885SIGMAR1 4684/4885 |
| US-20210038738-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | DDOST, DAD1, KRTCAP2 | KDM4E 2068/4885NPY5R 3527/4885SIGMAR1 4163/4885 |
| US-10314921-B2 | Antibody-drug-conjugate and its use for the treatment of cancer | KRTCAP2, DDOST, DAD1 | KDM4E 1659/4885NPY5R 3229/4885SIGMAR1 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.